Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70074 ↗Kurz gefasst
Scoping Review in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Marieke S Jansen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Decision Making, Stakeholder Participation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GetReal Institute.
Abstract (Originalsprache)
Purpose
Real‐world evidence (RWE) is increasingly considered in regulatory and health technology assessment (HTA) decision‐making, though perspectives on its relevance may vary. Expanding on a recent review regarding regulatory decisions, this study aimed to identify factors influencing the need for RWE in HTA decision‐making, confirm and enrich factors with stakeholder views, and evaluate similarities and differences between regulatory and HTA needs.
Methods
Previous scoping review methodology was used to identify factors influencing the need for RWE in HTA decision‐making. Semi‐structured interviews with stakeholders were conducted to confirm and enrich literature‐derived factors for both regulatory and HTA contexts. Insights from the reviews and interviews were combined to explore similarities and differences in RWE needs across these domains.
Results
The HTA review, featuring 118 articles, revealed two major themes and six subthemes, encompassing 45 factors. The need for RWE depended on (1) questions addressable with RWE, and (2) contextual factors. Stakeholder interviews confirmed literature‐derived factors. While contextual factors aligned between regulatory and HTA decision‐making, question‐related factors partly differed. Unlike the benefit–risk assessment in regulatory decision‐making, RWE serves as direct input for the HTA, and involves specific details and a broader scope. Regulators require RWE for orphan status submissions, alternative approval pathways and to evaluate the impact of risk minimization measures, whereas HTA uses RWE to guide comparator selection, evaluate treatment implementation, quality of care and general healthcare impacts.
Conclusion
Contextual factors that influence the need for RWE are similar between regulatory and HTA decision‐making, with variations seen in questions addressable with RWE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Endocrinology and Metabolic Disorders, Leiden University Medical Center, Leiden, The Netherlands.
- Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
- Cochrane Netherlands, University Medical Center Utrecht, Utrecht, The Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
ORCID-Profile: Marieke S Jansen, Olaf M Dekkers, Saskia le Cessie, Lotty Hooft, Helga Gardarsdottir, Anthonius de Boer, Rolf H H Groenwold
Förderung
- GetReal Institute
Zitieren
APA
Jansen, M. S., Dekkers, O. M., le Cessie, S., Hooft, L., Gardarsdottir, H., de Boer, A., & Groenwold, R. H. H. (2025). Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70074
Vancouver
Jansen MS, Dekkers OM, le Cessie S, Hooft L, Gardarsdottir H, de Boer A, et al. Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70074
BibTeX
@article{Jansen2025,
author = {Jansen, Marieke S and Dekkers, Olaf M and le Cessie, Saskia and Hooft, Lotty and Gardarsdottir, Helga and de Boer, Anthonius and Groenwold, Rolf H H},
title = {Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70074}
}
EUVIMED